Scheme 1a
a Reagent: (i) methanesulfonyl chloride, pyridine; (ii) B (Abz/
2-amino-6-chloropurine/Cz), K2CO3, DMF; (iii) NaOH, CH3OH,
H2O.
with the undesired N7 isomer in higher proportion. To
overcome this, 2 was alkylated with 2-amino-6-chloropurine,
which gave the N9 isomer 4a as a major product (90%).
The (2R,4S)-aepPNA monomers were likewise synthesized
from the diastereomer 1(2R,4R) with similar yields. The
hydrolysis of the methyl esters was effected with 1 N NaOH
in aqueous MeOH to get the desired PNA monomer synthons
3b-5b (2R/S,4S) in 95% yield. These and the corresponding
T monomer4 6 were individually incorporated into the PNA
sequences 8-11 by solid-phase synthesis using the standard
Boc-chemistry as previously reported.4 The unmodified PNA
7 and DNA 12, 13 sequences required for constituting the
duplexes were synthesized by standard procedures.
Figure 1. Strategies for the design of conformationally constrained
PNA analogues.
(2R,4S) or (2S,4S) backbone stereochemistry exhibited high
affinity and sequence specificity to form DNA:PNA2 tri-
plexes. Further, in such homopyrimidine aepPNA oligomers,
the nature of the backbone chirality was inconsequential in
differentiating the binding of complementary DNA in both
parallel (HG) and antiparallel (WC) orientations.6
In view of the above results, it was thought worthwhile
to examine the effect of aep backbone chirality on the
binding orientation in duplexes with mixed purine/pyrimidine
sequences. This and the combined characteristics of high
sequence specificity, affinity, improved aqueous solubility,
intrinsic positive charge, and the ease of synthesis of aepPNA
prompted us to construct aeg-aepPNA oligomers comprised
of pyrimidine-purine units and study preferences in duplex-
ation with DNA. We herein report the synthesis of (2S,4S)-
and (2R,4S)-aepPNA monomers of cytosine, adenine, and
guanine (3-5) and their incorporation, along with thymine4
6, in a control PNA sequence 7 at appropriate positions to
generate aeg-aepPNAs 8-11. Preliminary UV-Tm studies
of their binding with antiparallel and parallel complementary
DNA sequences (12, 13) reveal interesting stereochemical
and orientation preferences in PNA:DNA duplex formation.
Synthesis of aepPNA Monomers and aeg-aepPNAs. The
(2S,4S)-aep-PNA monomers 3-5 were synthesized (Scheme
1) by N-alkylation of protected nucleobases Abz, GiBu, and
CZ with the common intermediate 1-(N-Boc-aminoethyl)-
4(R)-O-mesyl-2(S)-proline methyl ester 2. This was obtained
from mesylation of the known (2S,4R) 4-hydroxyl com-
pound4 1 (45% yield). While Abz and CZ gave the expected
products 3a and 5a in 65% and 60% yield, respectively, GiBu
gave a mixture of N7:N9 alkylated products in a 5:1 ratio
All the modified PNA monomers were characterized by
1H and 13C NMR and mass spectrometry.7 The PNA
oligomers were purified by C18 reversed-phase HPLC and
(7) Characteristic signals. 3a (2S,4S): 1H NMR (CDCl3) δ 9.27 (br s,
1H, Benzamide-NH), 8.76 (s, 1H, A-H2), 8.70 (s, 1H, A-H8), 8.20 (m, 2H,
Bz, o-CH), 7.56 (m, 3H, Bz, p-CH, m-CH), 5.40 (m, 1H, H4), 5.15 (m,
1H, Boc-NH), 3.74 (s, 3H, OCH3), 3.60-2.60 (m, 9H, H5, H5′, H3, H3′,
H2, Boc-NH-(CH2)2), 1.45 (s, 9H, C(CH3)3); [R]25 ) +12° (c ) 0.1,
D
CH3OH). 3a (2R,4S): 1H NMR (CDCl3) δ 9.27 (br s, 1H, benzamide-NH),
8.76 (s, 1H, A-H2), 8.10 (s, 1H, A-H8), 8.00 (d, 2H, Bz, o-CH), 7.56 (t,
1H, Bz, p-CH), 7.45 (t, 2H, Bz, m-CH), 5.27 (m, 2H, H4, Boc-NH), 3.93
(m, 1H, H2), 3.74 (s, 3H, OCH3), 3.60 (m, 2H, H5, H5′), 3.20 (m, 2H, H3,
H3′), 2.83 (m, 2H, Boc-NH-CH2), 2.60 (m, 2H, Boc-NH-CH2CH2), 1.42
(s, 9H, C(CH3)3); [R]25D) +20.2° (c ) 0.1, CH3OH); MALDI-TOF M+)
509.6. 4a (2S,4S): 1H NMR (CDCl3) δ 8.35 (s, 1H, 2-amino-6-chloropurine,
H8), 5.20 (br s, 2H, N2H2), 5.10 (m, 2H, H4, Boc-NH), 3.75 (s, 3H, OCH3),
3.30 (m, 4H, H5, H5′, Boc-NH-CH2), 2.90 (m, 3H, H2, Boc-NHCH2CH2),
2.70 (m, 1H, H3), 2.15 (m, 1H, H3′), 1.45 (s, 9H, C(CH3)3); [R]25D ) -24°
(c ) 0.1, CH3OH). 4a (2R,4S): 1H NMR (CDCl3) δ 7.85 (s, 1H, 2-amino-
6-chloropurine, H8), 5.20 (m, 4H, N2H2, H4, NH), 3.92 (t, 1H, H2), 3.76
(s, 3H, OCH3), 3.60-3.00(br m, 4H, H5, H5′, H3, H3′), 2.84 (t, 2H, Boc-
NH-CH2), 2.56(t, 2H, Boc-NH-CH2CH2), 1.46 (s, 9H, C(CH3)3); [R]25
)
D
-4.8° (c ) 0.19, CH3OH); MALDI-TOF M + H ) 441.6. 5a (2S,4S): 1H
NMR (CDCl3) δ 8.45 (d, 1H, C-H6), 7.40 (s, 5H, Ph), 7.25 (d, 1H, C-H5),
5.35 (t, 1H, Boc-NH), 5.20 (s, 3H, Ph-CH2, H4), 3.75 (s, 3H, OCH3), 3.20
(br m, 4H, H5, H5′, Boc-NH-CH2), 2.80 (m, 2H, Boc-NH-CH2-CH2), 2.60
(m, 1H, H2), 1.90 (m, 2H, H3, H3′), 1.45 (s, 9H, C(CH3)3); [R]25D ) +9.6°
(c ) 0.3, CH3OH). 5a (2R,4S): 1H NMR (CDCl3) δ 7.90 (d, 1H, C-H6),
7.35 (s, 5H, Ph), 7.25 (d, 1H, C-H5), 5.40 (m, 1H, Boc-NH), 5.20 (s, 2H,
Ph-CH2), 4.90 (m, 1H, H4), 3.95 (dd, 1H, H5), 3.74 (s, 3H, OCH3), 3.40
(m, 1H, H5′), 3.25 (m, 2H, Boc-NH-CH2), 2.95 (m, 1H, H2), 2.77 (m, 2H,
Boc-NH-CH2CH2), 2.60 (m, 1H, H3), 2.15 (m, 1H, H3′), 1.45 (s, 9H,
C(CH3)3); [R]25 ) +24.2° (c ) 0.1, CH3OH); MALDI-TOF M + H )
D
517.7. PNA 8, 9, 10, 11: (MALDI-TOF) Mcalc)2796, Mobs)2796.
(8) Nielsen, P. E.; Egholm, M., Eds. Peptide Nucleic Acids: Protocols
and Applications; Horizon Scientific Press: Norfolk, England, 1999.
(6) parallel (p): N-end of PNA facing the 5′-end of DNA in the complex,
antiparallel (ap): C-end of PNA facing the 5′-end of DNA.
1282
Org. Lett., Vol. 3, No. 9, 2001